Hot COVID-19
Home > News > 6th Liquid Biopsy for Precision Oncology Summit 
Industry Updates New Products Supplier News Upcoming Events business web

6th Liquid Biopsy for Precision Oncology Summit 

Hits:245   Date: 12/3/2021
February 10-11, 2022 | Digital event
Free for Drug Developers & Researchers
Conference website: 
https://lbx-summit.com/

 
Reimagine Cancer Detection, Diagnosis & Patient Management through Harnessing the Potential of Liquid Biopsies
 
In the past year, the detection and characterization of fluid-based biomarkers in oncology witnessed an unprecedented level of progress, investment and industry partnership announcements. However, as the liquid assay landscape matures and the level of sensitivity and selectivity achieved by assays creates excitement for precision drug development, there remains a number of unique hurdles to translate rapid technical advancements seen towards the development of more effective and accessible precision oncology treatments.
 
That’s why the 6th Liquid Biopsy for Precision Oncology Summit will take place this February in San Diego, giving you the first opportunity in over a year to network, collaborate with and learn directly from your peers at a face-to-face forum.
 
As industry’s most comprehensive liquid biopsy meeting, unite with 300+ key decision makers including Pfizer, AstraZeneca, Mirati Therapeutics, Kura Oncology, GSK, BloodPAC, International Society of Liquid Biopsy, Guardant Health, Natera and many more to address the key scientific, technical, regulatory, commercial and testing access challenges associated with progressing precision oncology pipelines harnessing liquid biopsy technology.
 
With the rise of early detection and IO assays, expansion of MRD monitoring, CDx reimbursement announcements and a wealth of therapeutically relevant biomarkers being identified, here lies your prime opportunity to meet diverse stakeholders, in person, and discover the most cutting-edge scientific data to strengthen your pipeline and capitalize on the vast amount of progress the field is witnessing.





 
What's New for 2022?
 
Now expanding to 2-streams tackling the scientific applications & commercialization considerations it’s important we gather to address in tandem, here's what's new for 2022:
* Dive into latest industry consortium work by the  International Liquid Biopsy Standardization Alliance & FNIH to define quality control materials to see reproducible and reliable results
* Identify opportunities to leverage liquid biopsies to reveal new insights about cancer biology and potentially targetable biomarkers to inform new novel therapeutic strategies
* Discover how biopharma, including Pfizer & GSK, are using repeated liquid biopsy testing measurements to improve patient outcomes and reach more objective trial endpoints quicker
* Understand how assay sensitivity and specificity in the early detection setting is progressing and the potential of insights here to drive new preventative drug development strategies
* Strategize with your precision medicine peers as leaders address liquid biopsy implications for the valuation of drug programs and key decision making when it comes to planning your industry partners
* Navigate the reimbursement landscape from hearing how payors, clinicians and biopharma are addressing the underutilization of testing in today’s healthcare system to see greater return on your precision pipeline investments
 
From the vast amount of impressive data being witnessed today, it is clear liquid biopsy based biomarker detection and characterization is rapidly improving and gradually becoming a patient reality. As we address the multitude of opportunities liquid biopsies yield for improving the cancer-care continuum, from enabling earlier interventions to refining trial design and patient selection, this is your only opportunity to remain at the forefront of a fast-paced field witnessing huge progress year-on-year.
 
Join 300+ of your drug development peers from end-to-end drug development settings, as we leverage liquid biopsy technology to identify new biomarkers, accelerate biomarker-driven drug development and address all the commercialization components necessary to highlight the clinical utility of moving liquid biopsy testing into the current SOC.
 
Contact us
T: +1 617 455 4188
Email: info@hansonwade.com
advertisement